Benzinga | Oct 1, 2020 08:01AM EDT

Biocept To Present Study Results From Target Selector Testing In Cerebrospinal Fluid Of Patients With Lung Cancer At The IASLC Liquid Biopsy Meeting Oct. 2

SAN DIEGO, Oct. 1, 2020 /PRNewswire/ --Biocept, Inc. (NASDAQ:BIOC),a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the upcoming presentation of results from a prospective study using its Target Selector(tm) testing of the cerebrospinal fluid in patients with non-small lung cancer (NSCLC). The study results will be discussed in a poster presentation at the International Association for the Study of Lung Cancer (IASLC) Virtual Lung Cancer Hot Topic Meeting: Liquid Biopsy by David Berz, MD, PhD, MPH of the Beverly Hills Cancer Center, on October 2 from 2:30-3:30 p.m. Eastern time.